NewAmsterdam Pharma lands $196m Series A

NewAmsterdam Pharma, a clinical stage company focused on the research and development of transformative therapies for cardio-metabolic diseases, has raised $196 million in Series A funding.

NewAmsterdam Pharma, a clinical stage company focused on the research and development of transformative therapies for cardio-metabolic diseases, has raised $196 million in Series A funding. The investors included Forbion, Morningside Ventures and Ascendant BioCapital.

Source: Press Release